- Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. PubMed. Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/29773326. Accessed: 06/07/2018.
- Tremelimumab. National Cancer Institute. Retrieved from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tremelimumab. Accessed: 06/07/2018.
- Durvalumab. National Cancer Institute. Retrieved from: https://www.cancer.gov/about-cancer/treatment/drugs/durvalumab. Accessed: 06/07/2018.
- Durvalumab Injection. MedlinePlus. Retrieved from: https://medlineplus.gov/druginfo/meds/a617030.html. Accessed: 06/07/2018.
- A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma. ClinicalTrials.gov. Retrieved from: https://clinicaltrials.gov/ct2/show/NCT03075527?term=tremelimumab&cond=Mesothelioma&cntry=US&rank=1. Accessed: 06/07/2018.
- Mark Awad, MD, PhD. Dana-Farber Cancer Institute. Retrieved from: http://www.dana-farber.org/find-a-doctor/mark-awad/. Accessed: 06/07/2018.
- MARK M. AWAD, MD, PhD. DF/HCC Dana-Farber / Harvard Cancer Center. Retrieved from: http://www.dfhcc.harvard.edu/insider/member-detail/member/mark-m-awad-md-phd/. Accessed: 06/07/2018.
- Tremelimumab plus durvalumab active in unresectable mesothelioma. Medicine Matters. Retrieved from: https://oncology.medicinematters.com/mesothelioma/tremelimumab/tremelimumab-plus-durvalumab-active-in-unresectable-mesothelioma/15778432. Accessed: 06/12/2018.
Sources & Author